In a pivotal Assembly Public Safety Committee meeting on July 1, 2025, California lawmakers took significant steps toward addressing the growing crisis surrounding the dangerous substance Xylazine, commonly known as "tranq." The committee voted to advance legislation that would classify Xylazine as a Schedule 3 controlled substance, a move aimed at curbing its availability and protecting vulnerable communities.

Assemblymember Harbitti passionately highlighted the urgent need for improved funding and resources for rehabilitation and addiction services, emphasizing that current efforts are insufficient to meet the needs of those affected. "We collectively have to do a better job of making sure that we do keep the promise and provide treatment," he stated, expressing frustration over the ongoing challenges faced by individuals struggling with substance use.

The discussion also featured emotional testimonies from witnesses, including a veterinarian and a grieving parent, who underscored the lethal consequences of Xylazine use. Senator Ashby, the bill's author, echoed their sentiments, urging colleagues to recognize the drug's dangers. "It is lethal," he asserted, calling for a united effort to combat the crisis.

Assemblymember Lackey reinforced the necessity of the legislation, arguing that recognizing Xylazine as a controlled substance is a common-sense approach to addressing its misuse. He noted the importance of providing law enforcement with the tools needed to combat open drug dealing in communities.

The committee's decision to move the bill forward marks a critical step in California's ongoing battle against substance abuse, with lawmakers acknowledging the need for a multifaceted approach that includes both enforcement and support for treatment services. As the legislation progresses, the hope is to create a safer environment for all Californians while addressing the root causes of addiction.